Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 897076, 8 pages
http://dx.doi.org/10.1155/2012/897076
Research Article

Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice

1Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Via Fossato di Mortara 74, 44100 Ferrara, Italy
2Department of Physical and Rehabilitation Medicine, Rizzoli-Sicily IOR, 90011 Bagheria, Italy
3Department of Neurological Sciences and Vision, Section of Clinical Neurology, University of Verona, 37129 Verona, Italy
4Department of Biology and Evolution, University of Ferrara, 44121 Ferrara, Italy
5IGM-CNR, Unit of Bologna, c/o IOR, 40136 Bologna, Italy
6Department of Environmental and Life Sciences INSTM, University of Eastern Piedmont, 15121 Alessandria, Italy
7Department of Histology, Microbiology, and Medical Biotechnology, University of Padua, 35121 Padua, Italy

Received 21 March 2012; Revised 25 May 2012; Accepted 14 June 2012

Academic Editor: Steve Winder

Copyright © 2012 Elena Bassi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Aartsma-Rus, J. C. T. Van Deutekom, I. F. Fokkema, G. J. B. Van Ommen, and J. T. Den Dunnen, “Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule,” Muscle and Nerve, vol. 34, no. 2, pp. 135–144, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Aartsma-Rus and G. J. B. Van Ommen, “Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications,” RNA, vol. 13, no. 10, pp. 1609–1624, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. E. P. Hoffman, “Skipping toward personalized molecular medicine,” The New England Journal of Medicine, vol. 357, no. 26, pp. 2719–2722, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. Du and R. A. Gatti, “Progress toward therapy with antisense-mediated splicing modulation,” Current Opinion in Molecular Therapeutics, vol. 11, pp. 116–123, 2009. View at Google Scholar
  5. J. C. van Deutekom, A. A. Janson, I. B. Ginjaar et al., “Local dystrophin restoration with antisense oligonucleotide PRO051,” The New England Journal of Medicine, vol. 357, no. 26, pp. 2677–2686, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kinali, V. Arechavala-Gomeza, L. Feng et al., “Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study,” The Lancet Neurology, vol. 8, no. 10, pp. 918–928, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. N. M. Goemans, M. Tulinius, J. T. van den Akker et al., “Systemic administration of PRO051 in Duchenne's muscular dystrophy,” The New England Journal of Medicine, vol. 364, no. 16, pp. 1513–1522, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Cirak, V. Arechavala-Gomeza, M. Guglieri et al., “Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study,” The Lancet, vol. 378, no. 9791, pp. 595–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Williams, R. C. Schray, S. R. Sirsi, and G. J. Lutz, “Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice,” BMC Biotechnology, vol. 8, article 35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Kim, M. Tewari, J. D. Pajerowski et al., “Polymersome delivery of siRNA and antisense oligonucleotides,” Journal of Controlled Release, vol. 134, no. 2, pp. 132–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. R. Sirsi, R. C. Schray, X. Guan et al., “Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice,” Human Gene Therapy, vol. 19, no. 8, pp. 795–806, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Tao, J. P. Davide, M. Cai et al., “Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver,” Molecular Therapy, vol. 18, no. 9, pp. 1657–1666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Z. Yang, S. Dou, T. M. Sun, C. Q. Mao, H. X. Wang, and J. Wang, “Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy,” Journal of Controlled Release, vol. 156, pp. 203–211, 2011. View at Google Scholar
  14. H. de Martimprey, J. R. Bertrand, C. Malvy, P. Couvreur, and C. Vauthier, “New core-shell nanoparticules for the intravenous delivery of sirna to experimental thyroid papillary carcinoma,” Pharmaceutical Research, vol. 27, no. 3, pp. 498–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Bertholon, C. Vauthier, and D. Labarre, “Complement activation by core-shell poly(isobutylcyanoacrylate)- polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide,” Pharmaceutical Research, vol. 23, no. 6, pp. 1313–1323, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. M. E. Davis, J. E. Zuckerman, C. H. J. Choi et al., “Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles,” Nature, vol. 464, no. 7291, pp. 1067–1070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Rimessi, P. Sabatelli, M. Fabris et al., “Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse,” Molecular Therapy, vol. 17, no. 5, pp. 820–827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ferlini, P. Sabatelli, M. Fabris et al., “Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes,” Gene Therapy, vol. 17, no. 3, pp. 432–438, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Heemskerk, C. de Winter, P. Van Kuik et al., “Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model,” Molecular Therapy, vol. 18, no. 6, pp. 1210–1217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Ferlini and P. Rimessi, “Exon skipping quantification by real-time PCR,” Methods in Molecular Biology, vol. 867, pp. 189–199, 2012. View at Google Scholar
  21. P. Spitali, P. Rimessi, M. Fabris et al., “Exon skipping-mediated dystrophin reading frame restoration for small mutations,” Human Mutation, vol. 30, no. 11, pp. 1527–1534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. C. A. Sewry, “Immunocytochemical analysis of human muscular dystrophy,” Microscopy Research and Technique, vol. 48, no. 3-4, pp. 142–154, 2000. View at Google Scholar · View at Scopus
  23. R. Kayali, F. Bury, M. Ballard, and C. Bertoni, “Site-directed gene repair of the dystrophin gene mediated by PNA-ssODNs,” Human Molecular Genetics, vol. 19, no. 16, pp. 3266–3281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Fletcher, K. Honeyman, A. M. Fall, P. L. Harding, R. D. Johnsen, and S. D. Wilton, “Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligunucleotide,” Journal of Gene Medicine, vol. 8, no. 2, pp. 207–216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Alter, F. Lou, A. Rabinowitz et al., “Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology,” Nature Medicine, vol. 12, no. 2, pp. 175–177, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Wu, H. M. Moulton, P. L. Iversen et al., “Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 39, pp. 14814–14819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Jearawiriyapaisarn, H. M. Moulton, P. Sazani, R. Kole, and M. S. Willis, “Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers,” Cardiovascular Research, vol. 85, no. 3, pp. 444–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Yin, A. F. Saleh, C. Betts et al., “Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice,” Molecular Therapy, vol. 19, no. 7, pp. 1295–1303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. H. A. Heemskerk, C. L. de Winter, S. J. de Kimpe et al., “In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping,” Journal of Gene Medicine, vol. 11, no. 3, pp. 257–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. L. Qi, A. Rabinowitz, C. C. Yun et al., “Systemic delivery of antisense oligoribonucleotide restorers dystrophin expression in body-wide skeletal muscles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 198–203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Wu, P. Lu, E. Benrashid et al., “Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino,” Gene Therapy, vol. 17, no. 1, pp. 132–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Fletcher, K. Honeyman, A. M. Fall et al., “Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse,” Molecular Therapy, vol. 15, no. 9, pp. 1587–1592, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Jearawiriyapaisarn, H. M. Moulton, B. Buckley et al., “Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice,” Molecular Therapy, vol. 16, no. 9, pp. 1624–1629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Malerba, F. C. Thorogood, G. Dickson, and I. R. Graham, “Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice,” Human Gene Therapy, vol. 20, no. 9, pp. 955–965, 2009. View at Google Scholar · View at Scopus
  35. H. M. Moulton and J. D. Moulton, “Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy,” Biochimica et Biophysica Acta, vol. 1798, no. 12, pp. 2296–2303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. D. K. Monteith, M. J. Horner, N. A. Gillett et al., “Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys,” Toxicologic Pathology, vol. 27, no. 3, pp. 307–317, 1999. View at Google Scholar · View at Scopus
  37. E. S. Ferdinandi, A. Vassilakos, Y. Lee et al., “Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 1, pp. 193–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. D. J. Wells, K. E. Wells, E. A. Asante et al., “Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy,” Human Molecular Genetics, vol. 4, no. 8, pp. 1245–1250, 1995. View at Google Scholar · View at Scopus
  39. S. F. Phelps, M. A. Hauser, N. M. Cole et al., “Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice,” Human Molecular Genetics, vol. 4, no. 8, pp. 1251–1258, 1995. View at Google Scholar · View at Scopus
  40. M. Neri, S. Torelli, S. Brown et al., “Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human,” Neuromuscular Disorders, vol. 17, no. 11-12, pp. 913–918, 2007. View at Publisher · View at Google Scholar · View at Scopus